AVH
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Avita Medical, Inc. is a commercial-stage regenerative medicine company focused on therapeutic acute wound care and skin restoration. The company develops technologies to treat burns, traumatic injuries, and other complex wounds, supporting wound preparation, closure, and healing. Its primary product, RECELL, is an autologous skin cell suspension system approved by the U.S. Food and Drug Administration for thermal burn wounds and full-thickness skin defects, utilizing Spray-On Skin Cells for point-of-care closure. In the United States, the company also markets Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Internationally, RECELL and RECELL GO are CE-marked in Europe, TGA-certified in Australia, listed with Medsafe in New Zealand, and PMDA-approved in Japan. The company serves physicians and healthcare facilities in the U.S., Europe, Australia, New Zealand, and Japan.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Devices Homepage avitamedical.com
Sector Healthcare IR page ir.avitamedical.com/news-releases/news-release-details/avita-medical-host-investor-webinar-briefing-12
Tags
regenerative medicine, wound care, burn treatment, skin restoration, autologous cell therapy, dermal matrix, biosynthetic wound matrix, acute wound management, RECELL, Spray-On Skin Cells, Cohealyx, PermeaDerm, RECELL GO
Press page avitamedical.com/press-releases

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score -12.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 70.879M 63.893M 50.143M 34.421M 29.232M 14.263M 5.474M
Net profit -48.587M -61.845M -35.381M -26.665M -26.583M -42.03M -25.102M
Free cash flow -32.2M -58.11M -39.392M -19.542M -26.795M -23.337M -20.271M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 3.45 12.8 13.72 6.6 20.52 30.54 —
Price performance 12m -0.73 -0.07 1.08 -0.45 -0.33 — —

Filed figures

Figure Jun 2021 Jun 2022 Dec 2022 Jun 2023 Dec 2023 Jun 2024 Dec 2024 Jun 2025 Dec 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 3.47M 3.88M 3.52M 5.75M 7.66M 8.72M 11.8M 11.3M 9.09M 9.87M
↳ YoY growth +67.0% +12.0% +12.7% +48.1% +118.0% +51.5% +53.8% +30.1% -22.9% -13.0%
↳ 5y CAGR +44.1% +40.4% +36.2% +23.3%
Borrowings, current (USD) — — — — — — 0.00 — 43M 46.7M
Borrowings, non-current (USD) — — — — 39.8M 41M 42.2M 42.2M 0.00 —
Lease liabilities (USD) 1.58M 1.29M 918,000 1.7M 2.6M 4.1M 3.74M 2.37M 3.06M 1.82M
Cash and deposits (USD) 111M 34.7M 18.2M 37.5M 22.1M 17.5M 14.1M 12.2M 10.2M 9.14M
Intangible assets (USD) 472,000 428,000 465,000 456,000 487,000 545,000 5.57M 5.31M 5.65M 5.25M
Right-of-use assets (USD) 1.48M 1.2M 851,000 1.65M 2.44M 3.94M 3.57M 3.13M 2.9M 2.66M
Net debt (borrowings + leases - cash) (USD) — — — — 20.3M 27.6M 31.9M 32.4M 35.8M 39.3M
Cash flow detail
Operating cash flow (USD) -25.9M — -19.1M — -38M — -48.9M — -31.2M —
Purchases of property, plant and equipment (USD) -894,000 — -452,000 — -1.38M — -9.17M — -1.01M —
Purchases of intangible assets (USD) -280,000 — -73,000 — -66,000 — -162,000 — -99,000 —
Change in inventories (cash effect) (USD) -745,000 — -371,000 — -3.69M — -2.16M — -468,000 —
Change in payables (cash effect) (USD) -1.33M — 282,000 — 809,000 — 340,000 — 2.75M —
Interest paid (cash effect) (USD) -3,000 — -15,000 — -1.14M — -5.36M — -4.98M —
Income taxes paid (cash effect) (USD) -42,000 — -17,000 — -44,000 — -41,000 — -15,000 —
Share-based compensation (USD) 5.66M — 7M — 8.38M — 13.5M — 9.52M —
Free cash flow (OCF - PPE - intangibles) (USD) -27.1M — -19.6M — -39.5M — -58.3M — -32.3M —
Income detail
Research and development expense (USD) 14.8M — 13.9M — 20.8M — 20.4M — 20.8M —
Total comprehensive income (USD) -26.5M — -27.1M — -44.9M — -61.9M — -48M —
Comprehensive income to owners (USD) -26.5M — -27.1M — -44.9M — -61.9M — -48M —
Provision for credit losses (USD) 12,000 — 5,000 — 24,000 — 23,000 — -10,000 —
Credit cost ratio (credit losses / average receivables) (%) 0.4% — 0.2% — 0.4% — 0.2% — 0.1% —
Reported Aug 26, 2021 Aug 11, 2022 Feb 23, 2023 Aug 10, 2023 Feb 22, 2024 Aug 8, 2024 Nov 6, 2025 Aug 8, 2025 Feb 12, 2026 Aug 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

AVITA Medical Reports Complete Cohealyx I Data Bull 5 Bear 0 Clinical/regulatory
Cleansing Notice Bull 0 Bear 0 Routine
Notification regarding unquoted securities - AVH Bull 0 Bear 0 Routine

Prompts

Avita Medical, Inc. (ticker RCEL), listed in Australia.

Company History

Date Change Detail
Dec 16, 2020 Renamed AVITA THERAPEUTICS, INC. → AVITA MEDICAL, INC.
Jul 6, 2020 Renamed AVITA MEDICAL, LTD. → AVITA THERAPEUTICS, INC.
Dec 31, 2019 Reporting currency Its AU reports are in USD instead of AUD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

Securities

Ticker Type Class Market Exchange Last price Price date
RCEL Common share — US nasdaq 11.73 USD 2026-09-30
AVH canonical Common share — AU asx — —